{'52WeekChange': 1.5857143,
 'SandP52WeekChange': 0.0644362,
 'address1': '136a Eastern Avenue',
 'address2': 'Milton Park Oxfordshire',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 3.75,
 'askSize': 900,
 'averageDailyVolume10Day': 86637,
 'averageVolume': 117928,
 'averageVolume10days': 86637,
 'beta': 0.588235,
 'beta3Year': None,
 'bid': 3.64,
 'bidSize': 800,
 'bookValue': 2.255,
 'category': None,
 'circulatingSupply': None,
 'city': 'Abingdon',
 'companyOfficers': [],
 'country': 'United Kingdom',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 3.63,
 'dayLow': 3.48,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': None,
 'enterpriseValue': 243379488,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '44 12 3544 3999',
 'fiftyDayAverage': 3.368,
 'fiftyTwoWeekHigh': 5.49,
 'fiftyTwoWeekLow': 1.18,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 24810589,
 'forwardEps': -0.89,
 'forwardPE': -4.0674157,
 'fromCurrency': None,
 'fullTimeEmployees': 70,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.23289,
 'heldPercentInstitutions': 0.0853,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/summitplc.com',
 'longBusinessSummary': 'Summit Therapeutics plc, a biopharmaceutical company, '
                        'discovers, develops, and commercializes medicines to '
                        'treat infectious diseases in the United States, Latin '
                        'America, and Europe. It conducts clinical programs '
                        'focusing on the Clostridium difficile infection '
                        "(CDI). The company's lead product candidate is "
                        'ridinilazole, an orally administered small molecule '
                        'antibiotic that is in Phase III clinical trials for '
                        'the treatment of CDI. It also develops DDS-01 series '
                        'to treat infection caused by the bacteria Neisseria '
                        'gonorrhoeae through Discuva platform; and DDS-04 '
                        'series to treat Enterobacteriaceae. The company was '
                        'formerly known as Summit Corporation plc and changed '
                        'its name to Summit Therapeutics plc in February 2015. '
                        'Summit Therapeutics plc was founded in 2003 and is '
                        'based in Abingdon, the United Kingdom.',
 'longName': 'Summit Therapeutics plc',
 'market': 'us_market',
 'marketCap': 243379488,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_11611587',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': None,
 'nextFiscalYearEnd': 1640908800,
 'open': 3.53,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '44 12 3544 3939',
 'previousClose': 3.48,
 'priceHint': 4,
 'priceToBook': 1.6053214,
 'priceToSalesTrailing12Months': None,
 'profitMargins': -1.42601,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 3.63,
 'regularMarketDayLow': 3.48,
 'regularMarketOpen': 3.53,
 'regularMarketPreviousClose': 3.48,
 'regularMarketPrice': 3.53,
 'regularMarketVolume': 51737,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 67231904,
 'sharesPercentSharesOut': 0.00090000004,
 'sharesShort': 58633,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 46678,
 'shortName': 'Summit Therapeutics plc',
 'shortPercentOfFloat': None,
 'shortRatio': 0.54,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'SMMT',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': 1.225,
 'trailingPE': 2.955102,
 'twoHundredDayAverage': 2.7115972,
 'volume': 51737,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.summitplc.com',
 'yield': None,
 'ytdReturn': None,
 'zip': 'OX14 4SB'}